Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) announced its earnings results on Tuesday. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.03, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. The business had revenue of $881.71 million for the quarter, compared to the consensus estimate of $895.52 million.
Shionogi & Co., Ltd. Unsponsored ADR Stock Up 3.8%
OTCMKTS SGIOY traded up $0.36 during trading on Thursday, reaching $9.71. 16,239 shares of the company’s stock traded hands, compared to its average volume of 113,113. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21. The firm has a market cap of $16.52 billion, a price-to-earnings ratio of 12.13, a price-to-earnings-growth ratio of 0.65 and a beta of 0.10. The company’s 50 day simple moving average is $10.47 and its two-hundred day simple moving average is $9.78. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.45 and a 12-month high of $12.00.
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the stock. Zacks Research downgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 16th. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Reduce”.
Shionogi & Co., Ltd. Unsponsored ADR Company Profile
Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies.
Further Reading
- Five stocks we like better than Shionogi & Co., Ltd. Unsponsored ADR
- Why Satellogic Could Be One of the Biggest Space Winners of 2026
- Dividend Growth or High Yield: The Income Investor’s Bet
- A New Focus for GoPro: Is a Takeover in the Frame?
- Palantir’s Critics Are “Right”—But They’re Also Still Wrong
Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.
